News

The SMART trial's 3-year results showed that self-expanding supra-annular TAVR valves (Evolut platform, Medtronic) demonstrated superior hemodynamics and less thrombosis compared to balloon-expandable valves (Sapien platform, Edwards Lifesciences) in patients with small aortic annuli (≤430 mm²). There was no difference in the composite clinical endpoint of mortality, disabling stroke, or heart failure rehospitalization between groups (self-expanding 25.4% vs balloon-expandable 22.6%; HR 1.13, 95% CI 0.83-1.53, P=0.44).

Digest: These extended follow-up data support the use of self-expanding supra-annular valves for improved hemodynamic performance in small annuli patients, particularly relevant for lower-risk and younger TAVR candidates where long-term valve function is critical.

A study demonstrates that redo transcatheter aortic valve replacement using balloon-expandable valves is associated with favorable clinical outcomes and key procedural improvements. The findings support the safety and efficacy of repeat TAVR procedures in patients with failed bioprosthetic valves.

Digest: As the TAVR population ages and device durability becomes critical, establishing safety profiles for redo TAVR with specific valve platforms helps guide treatment decisions for structural valve degeneration.

Article discusses risk assessment strategies for patients who previously underwent TAVR and subsequently require non-cardiac or cardiac surgical procedures. Clinical considerations include evaluating perioperative risk in the context of existing bioprosthetic valves and potential complications.

Digest: As TAVR expands to younger, lower-risk populations, understanding how to manage these patients when they need subsequent surgical interventions becomes increasingly important for procedural planning and risk stratification.

Three-year follow-up data from the SMART trial continues to demonstrate superior structural valve deterioration outcomes for self-expanding TAVR valves compared to balloon-expandable systems. The durability advantage of self-expanding valves persisted at the 3-year time point.

Digest: This extends evidence supporting differential long-term durability between TAVR platform designs, which is critical for valve selection decisions particularly in younger, lower-risk patients where long-term performance drives clinical and economic outcomes.

New data suggest transcatheter aortic valve replacement (TAVR) may be overutilized in younger, lower-risk patients, prompting experts to issue a call to action regarding patient selection. The findings raise concerns about long-term durability and outcomes in patients with longer life expectancy who may require reintervention.

Digest: This challenges current practice patterns in TAVR patient selection and has implications for guideline adherence, long-term valve durability considerations, and the appropriate balance between TAVR and SAVR in younger populations.

Edwards Lifesciences' Resilia tissue, an integrity preservation technology for bioprosthetic heart valves, demonstrates favorable long-term durability outcomes. The tissue treatment is designed to reduce calcium buildup and improve structural valve deterioration resistance compared to conventional tissue.

Digest: Long-term durability data for Resilia tissue is critical for structural heart professionals evaluating valve choice in younger, lower-risk patients where extended valve longevity directly impacts reintervention rates and lifetime management strategies.

A study comparing outcomes of redo TAVR procedures found no significant differences between supra-annular and intra-annular valve designs. The findings suggest that valve positioning strategy does not substantially impact clinical outcomes in patients requiring repeat transcatheter aortic valve replacement.

Digest: This evidence supports flexibility in valve selection for redo TAVR procedures, potentially influencing procedural planning and device choice in the growing population of patients with failed bioprosthetic valves.

A five-year comparative study found that redo surgical mitral valve replacement outperformed transcatheter valve-in-valve mitral replacement for failed bioprosthetic mitral valves. The superior long-term outcomes of redo surgery over the transcatheter approach challenge current treatment preferences for this patient population.

Digest: This data may influence decision-making between redo surgical MVR and transcatheter valve-in-valve procedures, particularly in patients with acceptable surgical risk and longer life expectancy.